 | ||||||
| "anti diabetes" | ||||||
| WEB | ||||||
| Diabetes drug major USV looks at new growth opportunities USV, country's largest manufacturer of oral anti diabetes drugs, is stepping up its focus on biosimilars and niche low competition products in Europe and the US as it looks for new growth opportunities to achieve ~50 billion revenue in the next five years. It would have an estimated ~30 billion turnover for ...
| ||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.